Actively Recruiting
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
Led by Shanghai Chest Hospital · Updated on 2025-01-07
305
Participants Needed
11
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is: 1\) Whether MRD(Minimal residual disease) status can predict recurrence events in stage III driven-mutant NSCLC in advance
CONDITIONS
Official Title
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy
- Age≥ 18
- ECOG PS:0-1
- Tumor molecular testing by EBUS or biopsy confirmed positive for one or more of the following driver genes:EGFR\ALK\ROS1\RET\KRAS\PIK3CA\BRAF\HER2\MET
- Patients who met and agreed to surgery or radical chemoradiotherapy, and the remaining samples after cutting tissue sections did not affect the possible further clinical treatment of the subject
- Provide 20 mL peripheral blood samples periodically
- The subjects volunteered to join the study, and signed the informed consent form, with good compliance, and actively cooperated with the hospital for routine clinical diagnosis and treatment follow-up
You will not qualify if you...
- Patients with other malignancies within 5 years
- According to the investigator, the patient also had other diseases that may affect the follow-up and short-term survival
- The subject had other factors that may lead to the termination of the study, such as other serious diseases (including mental illness), serious laboratory abnormalities, and family or social factors that affected the safety of the subject, or the collection of data and samples
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Actively Recruiting
2
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Actively Recruiting
3
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Actively Recruiting
4
Hunan Cancer Hospital
Changsha, Hunan, China
Actively Recruiting
5
Shandong Provincial Hospital
Jinan, Shandong, China
Actively Recruiting
6
Shanghai Chest hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
7
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Actively Recruiting
8
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Actively Recruiting
9
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi’an, Shanxi, China
Actively Recruiting
10
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Actively Recruiting
11
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
Z
Ziming Li, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here